Abivax (NASDAQ:ABVX) reported quarterly losses of $(2.43) per share which missed the analyst consensus estimate of $(1.08) by 125 percent. This is a 65.31 percent decrease over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $2.959 million which beat the analyst consensus estimate of $1.860 million by 59.09 percent. This is a 61.71 percent decrease over sales of $7.727 million the same period last year.